OPN1SW and COVID-19: In line with this, Muthuramalingam and colleagues [126] have recently described BCP and BCPo as bioactive compounds capable of targeting COVID-19 immune genes implicated in different signalling pathways, extending the therapeutic potential of BCP to antiviral activity against COVID-19.